Accelerating VHH and bispecific antibody development is no longer just about speed, it’s about progressing the right candidates with confidence. Early insights into safety, immunogenicity, and developability are critical to reducing costly downstream risks and delays.

In this webinar, ProBio will showcase an integrated discovery strategy that combines single B-cell–based antibody discovery with advanced immunogenicity assessment. This approach enables rapid identification of high-quality candidates while providing early-stage insights to support smarter decision-making.

Topic Details

• Brief overview of current discovery strategy
• Introduction of a novel single B cell based discovery approach
• Case study with comparison between single B cell vs. phage display

• The origin and impact of immunogenicity
• Current bottleneck of immunogenicity evaluation
• ProBio’s one-stop solution of immunogenicity assessment

Reserve Your Spot Today!